Chemours Reports Q3 2025: Profit Amid Adjusted EBITDA Decline

Wilmington, Friday, 7 November 2025.
Chemours Company reported a Q3 net income of $60 million, but faced a decline in adjusted EBITDA. Despite strong Opteon sales, other segments underperformed, impacting future guidance.